Related Experiment Video
Updated: Apr 25, 2026
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
Growth hormone tumor histological subtypes predict response to surgical and medical therapy
Katja Kiseljak-Vassiliades1, Nichole E Carlson, Manuel T Borges
1Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, 12801 East 17th Ave, RC1 South Room 7402A, Aurora, CO, 80045, USA, katja.kiseljak-vassiliades@ucdenver.edu.
Abstract:
Growth hormone (GH) pituitary tumors are associated with significant morbidity and mortality. Current treatments, including surgery and medical therapy with somatostatin analogs (SSA), dopamine agonists and/or a GH receptor antagonist, result in disease remission in approximately half of patients. Predictors of GH tumor response to different therapies have been incompletely defined based on histologic subtype, particularly densely (DG) versus sparsely (SG) granulated adenomas. The aim of this study was to examine our own institutional experience with GH adenomas and correlate how subtype related to clinical parameters as well as response to surgery and medical therapies. A retrospective chart review of 101 acromegalic patients operated by a single neurosurgeon was performed. Clinical data were correlated with histologic subtype and disease control, as defined by IGF-1 levels, and random growth hormone levels in response to surgery and/or medical therapies. SG tumors, compared to DG, occurred in younger patients (p = 0.0010), were 3-fold larger (p = 0.0030) but showed no differences in tumor-invasion characteristics (p = 0.12). DG tumors had a higher rate of remission in response to surgery compared to SG, 65.7 vs. 14.3 % (p < 0.0001), as well as to medical therapy with SSAs (68.8 % for DG vs. 28.6 % for SG tumors; p = 0.028). SG tumors not controlled with SSAs consistently responded to a switch to, or addition of, a GH receptor antagonist. Histological GH tumor subtyping implicates a different clinical phenotype and biologic behavior, and provides prognostic significance for surgical success and response to medical therapies.
Insights
Histological subtypes of growth hormone (GH) pituitary tumors impact treatment response. Densely granulated tumors show better surgical and medical remission rates than sparsely granulated tumors, guiding personalized acromegaly therapy.
Area of Science:
- Endocrinology
- Neurosurgery
- Oncology
Background:
- Growth hormone (GH) pituitary tumors cause significant morbidity and mortality.
- Current treatments achieve remission in only about half of patients.
- Histologic subtypes (densely vs. sparsely granulated) may predict treatment response.
Purpose of the Study:
- To correlate GH adenoma subtype with clinical parameters and treatment response.
- To evaluate the prognostic significance of histologic subtyping for acromegaly management.
Main Methods:
- Retrospective chart review of 101 acromegalic patients.
- Correlation of clinical data with histologic subtype (densely vs. sparsely granulated).
- Assessment of disease control (IGF-1, GH levels) post-surgery and/or medical therapy.
Main Results:
- Sparsely granulated (SG) tumors occurred in younger patients and were larger than densely granulated (DG) tumors.
- DG tumors showed significantly higher remission rates after surgery (65.7% vs. 14.3%) and SSA therapy (68.8% vs. 28.6%) compared to SG tumors.
- SG tumors resistant to SSAs responded to GH receptor antagonists.
Conclusions:
- Histologic subtyping of GH adenomas reveals distinct clinical phenotypes and behaviors.
- Subtype classification provides prognostic value for surgical outcomes and medical therapy effectiveness in acromegaly.
- Tailoring treatment based on GH tumor subtype can improve patient management.
